



FOR IMMEDIATE RELEASE

Contacts:

For Ohmx Corporation:

Dimitra Georganopoulou

Tel: (847) 491-8513

Fax: (847) 491-8510

dimitra@ohmx.com

For Osmetech Corporation:

John Bellano

Senior Vice President, Commercial Operations

Tel: (626) 463-2000

Fax: (626) 463-2012

Osmetech licenses self-assembling monolayer (SAM) technology to Evanston, Illinois-based Ohmx Corporation

Osmetech plc (AIM; LSE) today announced that it has signed a non-exclusive commercial license with Evanston, Illinois-based Ohmx Corporation to Osmetech's self-assembling monolayer (SAM) technology for biosensor use. Ohm_x's current agreement with Osmetech is just the latest in a series of deals between Osmetech and Ohm_x. Ohm_x's founder and Chairman of the Board, Thomas Meade, Ph.D. also co-founded Clinical Micro Sensors and is an inventor on many of the California Institute of Technology's (Cal Tech) and Clinical Micro Sensors' (CMS) patents held or exclusively licensed by Osmetech. Financial details were not disclosed.

Osmetech, a fast developing, international diagnostics business with operations in Atlanta, Boston and Pasadena, USA serves the high growth, near patient molecular testing market and holds exclusive rights to the SAM technology. The SAM technology, invented by George Whitesides, Ph.D. at Harvard University, is finding increasing merit, particularly in electrochemistry-based biosensing methodologies, where it is used to minimize background signal, provide for uniform functionalized attachment of molecules and to reduce nonspecific aggregation events.

James White, CEO of Osmetech, said, "When Osmetech acquired CMS from Motorola, it came with a patent portfolio that had over \$25 million spent on it and over 80 granted patents. Today marks an important step in our ability to maximize our economic return by looking to actively license our portfolio to companies in complementary product areas and also for non-healthcare diagnostic markets such as research, forensics, environmental, biodefense and food. We look forward to announcing other partnerships in the near future."

"The SAM patents are just one complementary piece of a much broader intellectual property position held by Osmetech in the field of electrochemistry-based detection", says Edward Kreusser, Osmetech's VP of Intellectual Property and Legal Affairs. "In addition to the Harvard SAM IP, Osmetech also holds exclusive rights to very

valuable biosensing patents owned by Cal Tech, University of North Carolina, CMS and Concordia University”.

About Osmetech, Inc
(www.osmetech.com)

Osmetech plc is an AIM-listed public company on the London Stock Exchange under ticker symbol OMH. Osmetech plc is incorporated in England and Wales and its main country of operations is the US.

Osmetech plc was founded in 1993, developing electronic odour sensor (“e-nose”) technology. IPO followed in 1994 and in 1999, the Company changed its name from Aromascan to Osmetech refocusing the business on the opportunities within the global healthcare market. With the acquisition of the OPTI (blood gas) product line from Roche Diagnostics in 2003, the Critical Care Diagnostic Division was formed, which more than doubled its level of sales revenues in 3 years through a strong network of international distributors.

The Osmetech Molecular Diagnostics division was created from acquisitions of Molecular Sensing plc in October 2004 and Clinical Micro Sensors, Inc. from Motorola in July 2005. Recently, Osmetech divested its Critical Care Diagnostic Division and is now focused on accelerating the expansion and development of the Molecular Diagnostic Division.

About the Company:

Ohmx is advancing e-Diagnostics by developing a home monitoring device that can quantify clinical biomarkers and other important disease indicators from a finger prick. Ohmx’s handheld monitoring device is electric, low-cost, user-friendly, contains advanced communications protocols and can be used as a near-patient analyzer in the convenience of the patient’s home. Except for diabetes, there are few consumer devices that can monitor chronic diseases. Ohmx systems address this unmet need by offering a comprehensive platform for tests routinely used for chronic disease monitoring, including cardiac markers, blood gases, electrolytes, metabolites, lipids, cholesterol, glucose, glycosylated serum proteins and hemoglobin. Ohmx Founder and Chairman is Thomas Meade, PhD, who sold his prior company to Motorola for \$300M; President and CEO is Gary Blackurn, PhD (Boehringer, IGEN), and R&D is headed by Dimitra Georganopoulou, PhD (Inverness, Nanosphere). Ohmx seeks to raise \$10M to fund ongoing product development, manufacturing, and product launch. The Company has raised \$6.6M to date.

This press release may contain forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from the results identified or implied in any forward-looking statement. These statements are based on our views as of the date they are made with respect to future results or events. The Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results or events expressed or implied therein will not be realized.